Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Additional Studies Demonstrate PuriCore's Sterilox Solution Effective against Major Outbreak Pathogens

18 Jun 2007 12:00

PuriCore (LSE: PURI), the life sciences company focused on thedevelopment and commercialization of its novel, safe antimicrobialtechnology, will present results of several recent studies showingthat its Sterilox Solution effectively decontaminates hard surfacesinfected with norovirus, methicillin-resistant Staphylococcus aureus(MRSA), Acinetobacter, and human influenza--all considered majoroutbreak pathogens--at the National Environmental Health AssociationConference (NEHA) this week. The Sterilox Solution, which mimics thenatural anti-microbial hypochlorous acid produced by the human body tofight pathogens, is used in a broad range of markets that depend uponcontrolling contamination, including food safety, medical devicedisinfection, wound management, and hospitality. £ One of the studies, conducted by the research team of Dr. MarkSobsey at the University of North Carolina (UNC), tested theeffectiveness of the Sterilox Solution in decontaminating norovirus,the most frequent cause of viral gastroenteritis outbreaks worldwide,in both laboratory tests and a real-world, room-decontaminationsetting. The study showed that the Sterilox Solution, whenadministered as a spray or as a fog, was rapidly effective atdisinfecting room surfaces contaminated with norovirus. Theresearchers utilized a norovirus strain obtained from an actualoutbreak (rather than a commonly tested surrogate), and the tests wereperformed successfully on both porous and non-porous surfaces. £ "These studies continue to demonstrate that our safe andenvironmentally friendly Sterilox Solution is highly effective againstthe spread of these pathogens," said Greg Bosch, CEO of PuriCore. "Ourtechnology has potential for use in a variety of settings fromhospitals, schools, and supermarkets to hotels, cruise ships, andother public facilities." £ Mark Sampson, PhD, PuriCore's Director of Microbiology, willpresent results of the UNC norovirus study on Thursday, June 21, atthe NEHA Conference in Atlantic City, New Jersey, and at theAerobiology in Biodefense II Conference, sponsored by the NationalInstitutes of Health and the US Army Medical Research Institute, inJuly. In addition, results of this study will be published in the nextissue of The Journal of Applied and Environmental Microbiology(abstract available). £ Dr. Sampson's NEHA presentation will also report results fromrecent studies published in the Journal of Hospital Infectionperformed by Dr. Steve Barrett's research team at Charing CrossHospital in London that demonstrated the antimicrobial activity of theSterilox Solution fog in decontaminating MRSA and Acinetobacterclinical isolates dried onto surfaces. In addition, he will presentfindings from studies performed at independent labs that demonstratedthe virucidal activity of the Sterilox Solution when sprayed or foggedagainst the human influenza virus (A/Hong Kong 68 Strain, a commonsurrogate for the pandemic H5N1 avian influenza strain) dried ontosurfaces. £ About PuriCore £ PuriCore (London Stock Exchange: PURI) is a life sciences companyfocused on developing and commercializing proprietary products thatsafely, effectively, and naturally kill contagious pathogens.PuriCore's technology provides a solution to a broad range of marketsthat depend upon controlling contamination, including food safety,medical device disinfection, wound management, and hospitality. TheCompany's proprietary technology mimics the human body's production ofthe natural antimicrobial hypochlorous acid, which is highly effectivein killing bacteria, viruses, and fungal spores. Deployinghypochlorous acid solutions as soaks, sprays, mists, and in otherforms, PuriCore's technology is designed to limit the spread ofinfectious disease, including major public health threats of M.tuberculosis, MRSA, E.coli, norovirus, avian influenza, HIV, poliovirus, Helicobater pylori, and Legionella. PuriCore is headquarteredin Malvern, Pennsylvania, with offices in Stafford, UK. £ To receive additional information on PuriCore, please visit ourweb site at www.puricore.com, which does not form part of this pressrelease. Copyright Business Wire 2007
Date   Source Headline
26th Mar 20197:00 amRNSCancellation of AIM Listing
25th Mar 20194:40 pmRNSSecond Price Monitoring Extn
25th Mar 20194:35 pmRNSPrice Monitoring Extension
20th Mar 201911:12 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
18th Mar 201910:31 amRNSForm 8.5 (EPT/RI) Earthport Plc
18th Mar 201910:30 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
15th Mar 20192:35 pmRNSResult of General Meeting
15th Mar 201910:09 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
14th Mar 201911:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
13th Mar 201910:48 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
12th Mar 201911:53 amRNSForm 8.3 - Realm Therapeutics PLC
12th Mar 201910:07 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
11th Mar 201910:30 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
8th Mar 201911:30 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
7th Mar 201911:16 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
6th Mar 20199:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
5th Mar 20199:32 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Mar 201911:41 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
1st Mar 201910:07 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
28th Feb 201911:14 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
27th Feb 20194:58 pmRNSForm 8.3 - Realm Therapeutics
27th Feb 20194:41 pmRNSSecond Price Monitoring Extn
27th Feb 20194:36 pmRNSPrice Monitoring Extension
27th Feb 201911:01 amGNWInvesco Ltd.: Form 8.3 - Realm Therapeutics PLC
26th Feb 201910:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
25th Feb 201910:08 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
22nd Feb 201911:36 amGNWInvesco Ltd.: Form 8.3 - Realm Therapeutics PLC
22nd Feb 201910:02 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
21st Feb 20194:34 pmRNSForm 8.3 - Realm Therapeutics plc
21st Feb 20194:26 pmRNSHolding(s) in Company
21st Feb 20194:26 pmRNSHolding(s) in Company
21st Feb 201912:36 pmGNWInvesco Ltd.: Form 8.3 - Realm Therapeutics Plc
21st Feb 20199:59 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Feb 201910:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
19th Feb 20192:05 pmRNSSecond Price Monitoring Extn
19th Feb 20192:00 pmRNSPrice Monitoring Extension
19th Feb 20199:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
18th Feb 20199:25 amRNSForm 8.5 (EPT/RI)Realm Therapeutics
18th Feb 20199:05 amRNSSecond Price Monitoring Extn
18th Feb 20199:00 amRNSPrice Monitoring Extension
18th Feb 20197:00 amRNSBlock listing Interim Review
18th Feb 20197:00 amRNSUpdate on Strategic Review Re-release
15th Feb 20196:20 pmRNSUpdate on Strategic Review
15th Feb 20199:22 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
13th Feb 201910:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
11th Feb 201910:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
7th Feb 20199:48 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
6th Feb 201910:48 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
5th Feb 20199:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Feb 201911:23 amRNSForm 8.5 (EPT/RI) Realm Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.